Remote patient monitoring has evolved from a digital health innovation into standard clinical practice, with 2026 data demonstrating improved patient outcomes and reduced healthcare expenditures. The Centers for Medicare & Medicaid Services has reinforced this trend through the 2026 Physician Fee Schedule, introducing two new CPT codes recognizing RPM's clinical and financial value. CPT 99445 reimburses for two to fifteen days of monitoring data, while CPT 99470 compensates for initial management time. However, commercial and Medicare Advantage payer policies diverge significantly from traditional Medicare coverage, requiring providers to understand individual insurer guidelines to optimize RPM program success and prevent claim denials. Verification of current coverage requirements directly with payers remains essential before claim submission.

The Centers for Medicare & Medicaid Services has proposed substantial modifications to remote physiologic monitoring and remote therapeutic monitoring services under the 2027 Medicare Physician Fee Schedule. These changes respond to Office of Inspector General concerns regarding oversight and appropriate utilization of remote monitoring programs. The proposals will significantly impact physician practices, digital health companies, and remote monitoring vendors regarding payment structures, coverage requirements, and billing practices. Organizations furnishing or supporting these services should carefully review the proposed changes and submit comments to CMS. The modifications affect both established RPM codes, which have been in effect since 2019 for digitally collected physiologic data analysis, and newer RTM codes implemented in 2022 for non-physiological device monitoring applications. These comprehensive regulatory adjustments require stakeholder attention to operational and financial implications.

The FDA's Center for Devices and Radiological Health established the Payor Communication Task Force to bridge the gap between device manufacturers and insurance companies, aiming to accelerate patient access to medical devices. While the FDA approves devices based on safety and effectiveness, payors make separate coverage and reimbursement decisions using different data requirements. This misalignment often causes delays between FDA authorization and insurance coverage. The task force facilitates programs including the Early Payor Feedback Program and Parallel Review with Medicare and Medicaid Services, enabling manufacturers to design clinical trials meeting both regulatory and payor requirements, thereby streamlining the path to patient access.

Le Français Withings frappe un grand coup outre-Atlantique, puisque la medtech fondée par Éric Carreel devient la seule entreprise européenne retenue par les autorités américaines pour le lancement d'un tout nouveau programme de santé.

The pharmacovigilance outsourcing market is projected to double from $8.3 billion to $16.3 billion, signaling fundamental structural shifts in pharmaceutical drug safety monitoring rather than routine market expansion. This growth is driven by increasing clinical trial volumes, regulatory complexity, and the emergence of specialized therapies such as immunotherapies and antibody drug conjugates that require expert monitoring. Oncology represents the largest therapeutic area at 27.5% market share, particularly demanding sophisticated adverse event surveillance. Rather than purely cost-driven, outsourcing reflects strategic capability gaps, with small and mid-sized biotechs lacking in-house resources for equivalent safety infrastructure. However, regional regulatory divergence, data privacy regulations including GDPR, and scarce qualified pharmacovigilance talent present ongoing market challenges requiring sophisticated partner solutions.

The patient must use the IoT health monitoring device for at least 16 days a month to bill for CPT codes 99453 and 99454. CPT code 99454 pays for supplying the ...

Artificial intelligence is transforming pharmacovigilance by automating the detection and analysis of adverse drug events, significantly enhancing pharmaceutical safety monitoring. IntuitionLabs, founded by Adrien Laurent with over 25 years of enterprise software expertise, specializes in developing custom AI solutions for the pharmaceutical and life science sectors. The company leverages advanced technologies to help organizations navigate complex regulatory challenges and improve their adverse event detection capabilities. As a San Jose-based AI software development firm, IntuitionLabs focuses on enabling life science companies to effectively implement and harness artificial intelligence for enhanced operational efficiency and patient safety outcomes.

This document provides educational guidance on Quality Management Systems (QMS) for AI/ML medical devices, addressing regulatory compliance and design considerations. IntuitionLabs, a specialized AI software development firm founded in 2023, offers expertise in helping life science companies implement AI solutions. The content emphasizes the importance of independent verification of information and consulting qualified professionals for specific regulatory guidance. While the document may incorporate AI-generated content, readers should exercise caution regarding potential errors or omissions. This resource serves as an informational overview rather than professional or legal advice, requiring supplementary consultation with industry experts for comprehensive regulatory strategy and implementation.

The FDA's 2026 cybersecurity updates represent a fundamental transition from voluntary guidelines to mandatory requirements for connected medical devices. Effective February 2, 2026, cybersecurity becomes integrated into the Quality Management System Regulation, embedding security directly into product quality standards rather than treating it as a separate function. Under Section 524B of the FD&C Act, manufacturers must now adopt a Secure Product Development Framework, implementing security measures throughout the entire device lifecycle from design to decommissioning. Non-compliance constitutes a prohibited act with potential regulatory penalties and operational disruptions. Manufacturers must align with recognized standards such as IEC 81001-5-1 and document all cybersecurity efforts within the Design History File for FDA review. This enforcement shift reflects the regulatory body's commitment to enhancing patient safety and data integrity in connected medical devices.

The FDA has released updated cybersecurity guidance for medical device manufacturers, superseding its previous 2025 guidance. While non-binding, the guidance emphasizes that cybersecurity risk management is critical to ensuring devices remain safe and effective. Medical devices remain prime targets for cyber criminals, making robust security practices essential. The guidance supplements existing premarket and postmarket cybersecurity directives and aligns with broader federal cybersecurity initiatives, including the White House's Cyber Strategy for America. Rather than mandating specific technical measures, the FDA recommends manufacturers assess various cybersecurity controls during premarket submissions, such as secure design and architecture, while incorporating the ISO 13485 risk management framework. Companies should review their practices to meet FDA expectations and fulfill statutory obligations.

IntuitionLabs addresses critical challenges in AI post-market surveillance for the pharmaceutical and life sciences industries. Founded in 2023 by Adrien Laurent, the company specializes in custom AI solutions drawing on 25+ years of enterprise software expertise. This educational resource explores the distinction between locked and continuous learning approaches in AI monitoring systems, relevant to evolving FDA regulatory frameworks. The document emphasizes that readers should independently verify critical information and consult qualified professionals for specific business guidance, as AI-generated content may contain errors or omissions requiring careful review.

The FDA is increasingly requiring AI and machine learning-based medical devices to demonstrate explainability alongside strong performance metrics. While manufacturers have traditionally focused on developing sophisticated algorithms with high validation accuracy, regulatory reviewers now demand comprehensive documentation of how these models function, their limitations, and their clinical implications. The agency recognizes that clinicians must understand and potentially intervene in AI-generated diagnoses or treatment recommendations, rather than accepting black-box outputs regardless of accuracy. This shift reflects the FDA's commitment to ensuring patient safety by enabling informed clinical decision-making. Manufacturers submitting 510(k) and De Novo applications must therefore prioritize transparency and interpretability, addressing deficiency letters that challenge algorithmic opacity and substantiating clinician trust in these medical devices.

The FDA faces significant challenges regulating adaptive artificial intelligence medical devices as technology rapidly evolves beyond existing regulatory frameworks. With approximately 1,450 AI-enabled medical devices already authorized and generative AI entering clinical settings, the agency's statutory authority—designed for static hardware—proves inadequate for software that learns and adapts post-deployment. Most devices were cleared via the 510(k) pathway, concentrated in radiology, cardiology, and neurology. The fundamental challenge is that machine learning algorithms can materially change after market approval through continuous updates, unlike traditional devices with fixed functionality. The Government Accountability Office has formally recommended the FDA identify necessary statutory changes and communicate them to Congress, underscoring the regulatory framework's unsettled status and high-stakes implications for patient safety.

The FDA has relied on CDISC's Study Data Tabulation Model (SDTM) as the mandatory standard for organizing clinical trial data submissions since 2004. However, this foundational infrastructure is undergoing its most significant overhaul in two decades as modern drug development has become exponentially more complex. Contemporary trials now incorporate decentralized studies, adaptive designs, cell and gene therapies, and real-world evidence—challenges the SDTM framework was not designed to address. Current limitations became apparent in complex oncology trials featuring rescreening and re-enrollment protocols, where the existing data structure struggled to accommodate multiple participant iterations within a single trial. This modernization effort reflects the critical need to update data standardization practices to support evolving clinical research methodologies and ensure continued FDA regulatory efficiency.

Healthcare cybersecurity has evolved from a purely technical IT function to a critical operational and patient safety concern. Modern healthcare organizations depend heavily on interconnected digital infrastructure, including electronic health records, medical devices, and scheduling systems. When cyberattacks occur, they cascade across these integrated systems, disrupting clinical workflows, delaying procedures, and forcing organizations to revert to manual processes that increase error risk. Recent ransomware incidents demonstrate that cybersecurity threats now directly impact care delivery, financial stability, and regulatory compliance. Healthcare institutions must recognize cyber risk as an operational risk requiring coordination across clinical, compliance, and operational leadership rather than treating it as an isolated IT responsibility.

Infusion providers are increasingly deploying artificial intelligence tools for prior authorization, clinical documentation, revenue cycle management, and patient scheduling. However, many organizations lack adequate legal and compliance frameworks to manage the substantial regulatory and liability risks these technologies introduce. Without proper governance structures, infusion providers face exposure under HIPAA, the False Claims Act, and emerging state AI regulations. Misclassification or misuse of AI in clinical decision-making or billing workflows can create significant compliance gaps affecting operations and transaction value. For providers considering strategic transactions, AI governance is now a critical due diligence consideration. Best practices include conducting a comprehensive AI tool inventory, ensuring HIPAA-compliant vendor agreements, implementing human oversight in billing applications, and establishing formal written AI governance policies to address evolving regulatory requirements.

Researchers from Peking University and the California Institute of Technology have developed a breakthrough bioelectronic interface called SIRES (Strain-Resilient Intrinsically Stretchable Electrochemical biointerface). This innovative platform addresses a critical challenge in soft bioelectronics by enabling molecular sensors to maintain accurate readings while attached to moving biological tissues that stretch and deform. The technology maintains high-fidelity electrochemical outputs under tensile strains up to 300% and supports multiple sensing modes including voltammetric, amperometric, and potentiometric detection. Led by Prof. Yadong Xu and Professor Wei Gao, the research demonstrates applications in both wearable and implantable formats, including sweat monitoring, opening new possibilities for continuous health monitoring and molecular signal tracking on dynamic tissues.

Generative AI is revolutionizing healthcare through diverse applications that enhance clinical efficiency and patient outcomes. This comprehensive resource explores seventeen distinct use cases where AI technologies are being deployed across the healthcare sector. The applications span diagnostic assistance, treatment optimization, administrative automation, and clinical decision support. By leveraging large language models and advanced AI frameworks, healthcare organizations can streamline workflows, reduce operational costs, and improve care quality. These use cases demonstrate AI's transformative potential in addressing critical healthcare challenges, from personalized medicine to data management. The integration of generative AI in healthcare represents a significant advancement in modern medical practice, offering practitioners and administrators powerful tools to enhance service delivery while maintaining security and compliance standards.

The FDA has updated its guidance on real-world evidence, removing a significant barrier by allowing medical device sponsors to submit de-identified data in regulatory submissions. Previously, the agency required individually identifiable patient-level data, which restricted access to large-scale de-identified datasets from electronic health records, insurance claims, and disease registries. This December 2025 policy shift signals the FDA's growing willingness to engage with practical realities of modern clinical evidence generation. The change is expected to facilitate broader adoption of real-world evidence across medical devices and potentially influence how drug and biologic developers approach evidence collection and submission strategies.

Glucotrack’s Continuous Blood Glucose Monitor (CBGM) is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. The Glucotrack CBGM is an Investigational Device and is limited by federal (or United States) law to investigational use.